Healthcare-arkiv - Sida 2 av 28

Healthcare

Rights issue in Cantargia AB (SE) — SEK 250 million

Healthcare

Directed share issue in Oncopeptides AB (SE) — SEK 436 million

Healthcare

Sale of Livio AB (SE) to GeneraLife, owned by KKR (US) – Amount not disclosed

Healthcare

Introduction of A- and B-share class structure in H. Lundbeck A/S and subsequent A- for B-share exchange offer to eligible shareholders by the Lundbeck Foundation

Healthcare

Acquistion of Respiratory Motion Inc (US) by Senzime AB (SE) – Amount not disclosed

Healthcare

Directed share issue in Senzime AB (SE) — SEK 100 million

Healthcare

Private placement in Cinclus Pharma Holding AB (SE) – SEK 241 million

Healthcare

Private placement of shares in A3P Biomedical AB (SE) – SEK 400 million

Healthcare

Rights issue in Coala-Life Group AB — SEK 150 million

Healthcare

Fully underwritten rights issue rights issue in Observe Medical ASA (NO) — NOK 180 million

Healthcare

Directed share issue in SyntheticMR AB — SEK 60 million

Healthcare

Transactions: Healthcare

Filter

Rights issue in Cantargia AB (SE) — SEK 250 million

Directed share issue in Oncopeptides AB (SE) — SEK 436 million

Sale of Livio AB (SE) to GeneraLife, owned by KKR (US) – Amount not disclosed

Introduction of A- and B-share class structure in H. Lundbeck A/S and subsequent A- for B-share exchange offer to eligible shareholders by the Lundbeck Foundation

Acquistion of Respiratory Motion Inc (US) by Senzime AB (SE) – Amount not disclosed

Directed share issue in Senzime AB (SE) — SEK 100 million

Private placement in Cinclus Pharma Holding AB (SE) – SEK 241 million

Private placement of shares in A3P Biomedical AB (SE) – SEK 400 million

Rights issue in Coala-Life Group AB — SEK 150 million

Fully underwritten rights issue rights issue in Observe Medical ASA (NO) — NOK 180 million

Directed share issue in SyntheticMR AB — SEK 60 million

Private placement in Hjemmelegene AS (NO) — NOK 70 million

PB Online

Carnegie Edge

Carnegie Sparkonto

Transactions: Healthcare

Filter

Rights issue in Cantargia AB (SE) — SEK 250 million

Directed share issue in Oncopeptides AB (SE) — SEK 436 million

Sale of Livio AB (SE) to GeneraLife, owned by KKR (US) – Amount not disclosed

Introduction of A- and B-share class structure in H. Lundbeck A/S and subsequent A- for B-share exchange offer to eligible shareholders by the Lundbeck Foundation

Acquistion of Respiratory Motion Inc (US) by Senzime AB (SE) – Amount not disclosed

Directed share issue in Senzime AB (SE) — SEK 100 million

Private placement in Cinclus Pharma Holding AB (SE) – SEK 241 million

Private placement of shares in A3P Biomedical AB (SE) – SEK 400 million

Rights issue in Coala-Life Group AB — SEK 150 million

Fully underwritten rights issue rights issue in Observe Medical ASA (NO) — NOK 180 million

Directed share issue in SyntheticMR AB — SEK 60 million

Private placement in Hjemmelegene AS (NO) — NOK 70 million